UFPTNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

UFP Technologies, Inc

UFP Technologies is a U.S.-based contract development and manufacturing company focused on single-use and single-patient medical devices and components. Its products are custom-engineered for medical device manufacturers and are used in areas such as minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.

Liikevaihto603milj. USD
Liikevoitto (EBIT)92,3milj. USD
+14,1 %v/v
EBIT-marginaali15,3%
Nettotulos68,3milj. USD
+15,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

0200400600800milj. USD2020: EBIT 17 milj. USD20202021: EBIT 21 milj. USD20212022: EBIT 55 milj. USD20222023: EBIT 58 milj. USD20232024: EBIT 81 milj. USD20242025: 603 milj. USD2025: EBIT 92 milj. USD202560392
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Single-use medical devices45 %

Custom disposable devices and components used once per patient or procedure.

Surgical and infection prevention products25 %

Products used in minimally invasive surgery, infection control, and procedural protection.

Orthopedic and implant-related components15 %

Soft goods, packaging, and components used in orthopedic and implant applications.

Wearables and patient care products10 %

Comfort, support, and patient-handling products for medical use.

Biopharma and other specialty applications5 %

Specialty manufacturing components and niche medical-market applications.

Tuotteet

Raportoitu · osuus liikevaihdosta
98,1%FY2025100 %
  • Products98,1 %
  • Engineering and Development1,2 %
  • Tooling and Machinery0,7 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

UFP Technologies sells primarily to medical device manufacturers that outsource development and production of specialized disposable components. Its customer base includes large OEMs in minimally invasive surgery, orthopedics, infection prevention, and other medical end markets, where custom design and manufacturing speed matter. The company also serves biopharma-related customers for specialized manufacturing components.

Medical device OEMs

Buy custom-engineered single-use devices and components for integration into finished medical products.

Minimally invasive surgery platforms

Buy drapes, disposables, and protective components used in robotic and endoscopic procedures.

Orthopedic manufacturers

Buy soft goods, packaging, and implant-related components for orthopedic applications.

Infection prevention and wound care customers

Buy specialty materials and disposables designed to reduce contamination and improve patient care.

Biopharma customers

Buy niche manufacturing components used in drug manufacturing and related processes.

Strategia

The company’s strategy centers on organic growth in specialized medical niches and expansion through acquisitions. It competes by combining engineering know-how, specialty materials, and custom manufacturing to help customers speed time to market and improve product performance.

Organic growth in medical nichesKeskipitkä aikaväli

Custom solutions and specialized materials support higher-value customer relationships.

Acquisition-led expansionLyhyt aikaväli

Acquisitions broaden the product set and customer base in adjacent medical categories.

Customer collaboration and direct salesKeskipitkä aikaväli

Direct engineering and commercial engagement helps win custom programs and retain OEM accounts.

Maantiede

UFP Technologies is headquartered in the United States and manufactures goods in the U.S. and outside the U.S. for global medical customers. Its end markets are international, but the business is operationally sensitive to trade policy because tariffs can affect both imported materials and cross-border manufacturing flows.

Riskit

UFP Technologies depends on a concentrated set of large medical customers, so volume losses or pricing pressure from a few accounts can materially affect results. The business also faces supply-chain, tariff, and integration risks because it relies on specialty materials, international manufacturing, and acquisitions to support growth.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Customer concentration1Tariff and trade policy exposure2Supply chain and materials risk3Acquisition integration risk4Regulatory and climate-related operating risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Customer concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Two customers represented a very large share of net sales, so loss or slowdown at either account would be material.

    Kohdistuu: Intuitive Surgical and Stryker

  2. Tariff and trade policy exposureVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The company manufactures outside the U.S. and buys materials that can be affected by import tariffs and retaliatory trade actions.

    Kohdistuu: Manufacturing and raw materials

  3. Supply chain and materials riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Custom medical products depend on specialized inputs and reliable supplier relationships.

    Kohdistuu: Specialty materials

  4. Acquisition integration riskVaikutus: KeskitasoTodennäköisyys: Matala

    Growth through acquisitions can create execution risk around systems, customers, and realized synergies.

    Kohdistuu: Recent acquisitions

  5. Regulatory and climate-related operating riskVaikutus: MatalaTodennäköisyys: Kohtalainen

    Medical manufacturing is exposed to changing regulations, customer standards, and physical supply disruptions.

    Kohdistuu: Facilities and supply chain

Kirjanpito

Harkinnanvaraiset erät
Goodwill and intangible assets

Acquisitions created a large intangible asset base that must be tested for impairment and amortized where applicable.

Vaikutus: Can cause non-cash charges and affect reported earnings

Deferred tax assets

Realization depends on future taxable income and may require valuation adjustments.

Vaikutus: Can change tax expense and net income

Debt and covenant accounting

Borrowings under the credit facility require compliance with financial covenants.

Vaikutus: Affects liquidity disclosure and going-concern risk assessment

Acquisition accounting

Purchase accounting allocates value to customer lists, trade names, and other intangibles.

Vaikutus: Affects amortization, goodwill, and post-deal comparability

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

UFP Technologies, Inc (UFPT) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo